These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Functional and radioligand binding characterization of the α1L-adrenoceptor subtype of the human vas deferens. Davis BJ; Wiener M; Chapple CR; Sellers DJ; Chess-Williams R Auton Autacoid Pharmacol; 2015 Apr; 34(3-4):41-9. PubMed ID: 25790239 [TBL] [Abstract][Full Text] [Related]
45. Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate. Hiraoka Y; Ohmura T; Oshita M; Watanabe Y; Morikawa K; Nagata O; Kato H; Taniguchi T; Muramatsu I Eur J Pharmacol; 1999 Jan; 366(1):119-26. PubMed ID: 10064160 [TBL] [Abstract][Full Text] [Related]
46. Chiral analogues of (+)-cyclazosin as potent α Sagratini G; Buccioni M; Marucci G; Poggesi E; Skorski M; Costanzi S; Giardinà D Bioorg Med Chem; 2018 Jul; 26(12):3502-3513. PubMed ID: 29784274 [TBL] [Abstract][Full Text] [Related]
47. The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries. Jensen BC; Swigart PM; Laden ME; DeMarco T; Hoopes C; Simpson PC J Am Coll Cardiol; 2009 Sep; 54(13):1137-45. PubMed ID: 19761933 [TBL] [Abstract][Full Text] [Related]
48. Pharmacological identification of α1- and α2-adrenoceptor subtypes involved in the vasopressor responses induced by ergotamine in pithed rats. Villamil-Hernández MT; Alcántara-Vázquez O; Sánchez-López A; Centurión D Eur J Pharmacol; 2013 Sep; 715(1-3):262-9. PubMed ID: 23707349 [TBL] [Abstract][Full Text] [Related]
49. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Kenny BA; Miller AM; Williamson IJ; O'Connell J; Chalmers DH; Naylor AM Br J Pharmacol; 1996 Jun; 118(4):871-8. PubMed ID: 8799556 [TBL] [Abstract][Full Text] [Related]
50. Alpha1-adrenoceptor subtypes and two receptor systems in vascular tissues. Muramatsu I; Murata S; Isaka M; Piao HL; Zhu J; Suzuki F; Miyamoto S; Oshita M; Watanabe Y; Taniguchi T Life Sci; 1998; 62(17-18):1461-5. PubMed ID: 9585119 [TBL] [Abstract][Full Text] [Related]
51. 8-NH2-boldine, an antagonist of alpha1A and alpha1B adrenoceptors without affinity for the alpha1D subtype: structural requirements for aporphines at alpha1-adrenoceptor subtypes. Ivorra MD; Valiente M; Martínez S; Madrero Y; Noguera MA; Cassels BK; Sobarzo EM; D'Ocon P Planta Med; 2005 Oct; 71(10):897-903. PubMed ID: 16254819 [TBL] [Abstract][Full Text] [Related]
52. Isoxazolo-[3,4-d]-pyridazin-7-(6H)-ones and their corresponding 4,5-disubstituted-3-(2H)-pyridazinone analogues as new substrates for alpha1-adrenoceptor selective antagonists: synthesis, modeling, and binding studies. Montesano F; Barlocco D; Dal Piaz V; Leonardi A; Poggesi E; Fanelli F; De Benedetti PG Bioorg Med Chem; 1998 Jul; 6(7):925-35. PubMed ID: 9730228 [TBL] [Abstract][Full Text] [Related]
53. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Takei R; Ikegaki I; Shibata K; Tsujimoto G; Asano T Jpn J Pharmacol; 1999 Apr; 79(4):447-54. PubMed ID: 10361884 [TBL] [Abstract][Full Text] [Related]
54. In vitro studies on L-771,688 (SNAP 6383), a new potent and selective alpha1A-adrenoceptor antagonist. Chang RS; Chen TB; O'Malley SS; Pettibone DJ; DiSalvo J; Francis B; Bock MG; Freidinger R; Nagarathnam D; Miao SW; Shen Q; Lagu B; Murali Dhar TG; Tyagarajan S; Marzabadi MR; Wong WC; Gluchowski C; Forray C Eur J Pharmacol; 2000 Dec; 409(3):301-12. PubMed ID: 11108825 [TBL] [Abstract][Full Text] [Related]
55. Differential coupling of alpha1-adrenoreceptor subtypes to phospholipase C and mitogen activated protein kinase in neonatal rat cardiac myocytes. Wenham D; Rahmatullah RJ; Rahmatullah M; Hansen CA; Robishaw JD Eur J Pharmacol; 1997 Nov; 339(1):77-86. PubMed ID: 9450619 [TBL] [Abstract][Full Text] [Related]
56. Cycloalkanecarboxylic esters derived from lysergol, dihydrolysergol-I, and elymoclavine as partial agonists and antagonists at rat 5-HT2A receptors: pharmacological evidence that the indolo[4,3-fg]quinoline system of the ergolines is responsible for high 5-HT2A receptor affinity. Pertz HH; Milhahn H; Eich E J Med Chem; 1999 Feb; 42(4):659-68. PubMed ID: 10052973 [TBL] [Abstract][Full Text] [Related]
57. Involvement of α Alsufyani HA; Docherty JR Korean J Physiol Pharmacol; 2023 Jul; 27(4):325-331. PubMed ID: 37386830 [TBL] [Abstract][Full Text] [Related]
58. Contrasting signaling pathways of alpha1A- and alpha1B-adrenergic receptor subtype activation of phosphatidylinositol 3-kinase and Ras in transfected NIH3T3 cells. Hu ZW; Shi XY; Lin RZ; Hoffman BB Mol Endocrinol; 1999 Jan; 13(1):3-14. PubMed ID: 9892008 [TBL] [Abstract][Full Text] [Related]
59. Revisiting the Pharmacodynamic Uroselectivity of Quaresma BMCS; Pimenta AR; Santos da Silva AC; Pupo AS; Romeiro LAS; Silva CLM; Noël F J Pharmacol Exp Ther; 2019 Oct; 371(1):106-112. PubMed ID: 31285236 [TBL] [Abstract][Full Text] [Related]